Publikationen

Progress in cardiovascular diseases. 2021 Jun 27. doi: 10.1016/j.pcad.2021.06.010. pii: S0033-0620(21)00068-2

Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP).

Ruscica M¹, Penson PE², Ferri N³, Sirtori CR⁴, Pirro M⁵, Mancini GBJ⁶, Sattar N⁷, Toth PP⁸, Sahebkar A⁹, Lavie CJ¹⁰, Wong ND¹¹, Banach M¹²

Collaborators

Author information

¹Department of Pharmacology and Biomolecular Sciences, Università degli Studi di Milano, Milano, Italy.
²School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK; Liverpool Centre for Cardiovascular Science, Liverpool, UK.
³Department of Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, Padova, Italy.
⁴Department of Pharmacology and Biomolecular Sciences, Università degli Studi di Milano, Milano, Italy.
⁵Internal Medicine Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
⁶Center for Cardiovascular Innovation, University of British Columbia, Vancouver, BC, Canada.
⁷Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom.
⁸Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁹Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
¹⁰Department of Medicine, John Ochsner Medical Center, New Orleans, LA, USA.
¹¹Heart Disease Prevention Program, Division of Cardiology, University of California Irvine, Irvine, CA, USA.
¹²Department of Hypertension, Medical University of Lodz (MUL), Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland. Electronic address: maciej.banach@umed.lodz.pl.

Abstract

Inflammation is a marker of arterial disease stemming from cholesterol-dependent to -independent molecular mechanisms. In recent years, the role of inflammation in atherogenesis has been underpinned by pharmacological approaches targeting systemic inflammation that have led to a significant reduction in cardiovascular disease (CVD) risk. Although the use of nutraceuticals to prevent CVD has largely focused on lipid-lowering (e.g, red-yeast rice and omega-3 fatty acids), there is growing interest and need, especially now in the time of coronavirus pandemic, in the use of nutraceuticals to reduce inflammatory markers, and potentially the inflammatory CVD burden, however, there is still not enough evidence to confirm this. Indeed, diet is an important lifestyle determinant of health and can influence both systemic and vascular inflammation, to varying extents, according to the individual nutraceutical constituents. Thus, the aim of this Position Paper is to provide the first attempt at recommendations on the use of nutraceuticals with effective anti-inflammatory properties.

KEYWORDS: C-reactive protein, Cardiovascular disease, Inflammation, Nutraceuticals, Omega-3, Position paper, Red-yeast rice

Publikations ID: 34186099
Quelle: öffnen

Drucken

Schnellinfo

-- Initiative Krebsforschung / Krebsforschungslauf

-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt

Zuklappen

Ausklappen

Schnellinfo

Featured